Literature DB >> 31221780

Osteolytic disease in IL-6 and Myc dependent mouse model of human myeloma.

Fumou Sun1, Yan Cheng1, Susan A Walsh2, Michael R Acevedo2, Xuefang Jing3, Seong Su Han4, Michael D Pisano1,5, Michael H Tomasson6,7, Alan K Lichtenstein8, Fenghuang Zhan6,7, Parameswaran Hari1,9, Siegfried Janz10,9.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2019        PMID： 31221780      PMCID： PMC7049347          DOI： 10.3324/haematol.2019.221127

Source DB:  PubMed          Journal:  Haematologica        ISSN： 0390-6078            Impact factor:   9.941


× No keyword cloud information.
  15 in total

Review 1.  Current Controversies in the Management of Myeloma Bone Disease.

Authors:  Rebecca Silbermann; Garson David Roodman
Journal:  J Cell Physiol       Date:  2016-03-10       Impact factor: 6.384

2.  Preclinical animal models of multiple myeloma.

Authors:  Seint T Lwin; Claire M Edwards; Rebecca Silbermann
Journal:  Bonekey Rep       Date:  2016-02-03

3.  Denosumab versus zoledronic acid in bone disease treatment of newly diagnosed multiple myeloma: an international, double-blind, double-dummy, randomised, controlled, phase 3 study.

Authors:  Noopur Raje; Evangelos Terpos; Wolfgang Willenbacher; Kazuyuki Shimizu; Ramón García-Sanz; Brian Durie; Wojciech Legieć; Marta Krejčí; Kamel Laribi; Li Zhu; Paul Cheng; Douglas Warner; G David Roodman
Journal:  Lancet Oncol       Date:  2018-02-09       Impact factor: 41.316

Review 4.  Role of the RANK/RANKL Pathway in Multiple Myeloma.

Authors:  Noopur S Raje; Sumita Bhatta; Evangelos Terpos
Journal:  Clin Cancer Res       Date:  2018-08-09       Impact factor: 12.531

5.  Animal model of human disease. Multiple myeloma.

Authors:  J Radl; J W Croese; C Zurcher; M H Van den Enden-Vieveen; A M de Leeuw
Journal:  Am J Pathol       Date:  1988-09       Impact factor: 4.307

Review 6.  An Evidence-Based Approach to Myeloma Bone Disease.

Authors:  Nicholas Bingham; Antonia Reale; Andrew Spencer
Journal:  Curr Hematol Malig Rep       Date:  2017-04       Impact factor: 3.952

7.  Primary myeloma cells growing in SCID-hu mice: a model for studying the biology and treatment of myeloma and its manifestations.

Authors:  S Yaccoby; B Barlogie; J Epstein
Journal:  Blood       Date:  1998-10-15       Impact factor: 22.113

Review 8.  New agents in the Treatment of Myeloma Bone Disease.

Authors:  Elizabeth S Ring; Michelle A Lawson; John A Snowden; Ingrid Jolley; Andrew D Chantry
Journal:  Calcif Tissue Int       Date:  2017-11-02       Impact factor: 4.333

9.  A novel mouse model for multiple myeloma (MOPC315.BM) that allows noninvasive spatiotemporal detection of osteolytic disease.

Authors:  Peter O Hofgaard; Henriette C Jodal; Kurt Bommert; Bertrand Huard; Jo Caers; Harald Carlsen; Rolf Schwarzer; Nicole Schünemann; Franziska Jundt; Mona M Lindeberg; Bjarne Bogen
Journal:  PLoS One       Date:  2012-12-20       Impact factor: 3.240

Review 10.  Pathogenesis of bone disease in multiple myeloma: from bench to bedside.

Authors:  Evangelos Terpos; Ioannis Ntanasis-Stathopoulos; Maria Gavriatopoulou; Meletios A Dimopoulos
Journal:  Blood Cancer J       Date:  2018-01-12       Impact factor: 11.037
View more
  2 in total

1.  Critical Role for Cap-Independent c-MYC Translation in Progression of Multiple Myeloma.

Authors:  Yijiang Shi; Alan Lichtenstein; Fumou Sun; Yan Cheng; Brent Holmes; Binod Dhakal; Joseph F Gera; Siegfried Janz
Journal:  Mol Cancer Ther       Date:  2022-04-01       Impact factor: 6.009

Review 2.  Laboratory Mice - A Driving Force in Immunopathology and Immunotherapy Studies of Human Multiple Myeloma.

Authors:  Michael Pisano; Yan Cheng; Fumou Sun; Binod Dhakal; Anita D'Souza; Saurabh Chhabra; Jennifer M Knight; Sridhar Rao; Fenghuang Zhan; Parameswaran Hari; Siegfried Janz
Journal:  Front Immunol       Date:  2021-06-02       Impact factor: 7.561
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.